|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.140 USD | +6.54% |
|
+6.54% | -67.71% |
| 06-30 | ADC Therapeutics SA Completes Enrollment In LOTIS-7 Phase 1b ZYNLONTA Combination Trial | CI |
| 06-30 | ADC Therapeutics Completes Enrollment in LOTIS-7 Lymphoma Study | MT |
| Market Cap | 145M 127M 117M 109M 206M 13.79B 210M 1.41B 546M 6.77B 544M 533M 23.55B | P/E 2026 * |
-1.34x | P/E 2027 * | -1.72x |
|---|---|---|---|---|---|
| Enterprise Value | 145M 127M 117M 109M 206M 13.79B 210M 1.41B 546M 6.77B 544M 533M 23.55B | EV / Sales 2026 * |
1.78x | EV / Sales 2027 * | 1.17x |
| Free-Float |
84.85% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: ADC Therapeutics SA
| 1 day | +6.54% | ||
| 1 week | +6.54% | ||
| Current month | +6.54% | ||
| 1 month | -66.47% | ||
| 3 months | -70.00% | ||
| 6 months | -67.71% | ||
| Current year | -67.71% |
| 1 week | 1 |  | 1.18 |
| 1 month | 0.78 | | 3.18 |
| Current year | 0.78 | | 4.98 |
| 1 year | 0.78 | | 4.98 |
| 3 years | 0.36 | | 6.04 |
| 5 years | 0.36 | | 32 |
| 10 years | 0.36 | | 56.59 |
| Manager | Title | Age | Since |
|---|---|---|---|
Ameet Mallik
CEO | Chief Executive Officer | 53 | 2022-05-08 |
Jose Carmona
DFI | Director of Finance/CFO | 54 | 2022-12-18 |
David Ege
CTO | Chief Tech/Sci/R&D Officer | 52 | 2024-09-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Peter Hug
BRD | Director/Board Member | 67 | 2019-05-31 |
Tyrell Rivers
BRD | Director/Board Member | 53 | 2018-05-31 |
Ron Squarer
CHM | Chairman | 59 | 2020-02-29 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 06-02 | Tax | Director | -2,156 | 0.0017% | ||
| 06-02 | Tax | Director | -12,600 | 0.0099% | ||
| 06-02 | Tax | Director | -12,600 | 0.0099% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +6.54% | +6.54% | -57.30% | -46.98% | 136M | |
| -2.19% | +6.01% | +66.90% | +123.30% | 57.65B | |
| +0.55% | +8.49% | +77.09% | +100.93% | 55.14B | |
| +0.93% | +4.11% | -12.64% | -12.98% | 23.53B | |
| +0.36% | +3.42% | +9.61% | +407.11% | 23.11B | |
| +3.70% | +8.40% | +39.88% | -5.83% | 18.14B | |
| +0.28% | +5.51% | +36.93% | -30.23% | 16.84B | |
| +1.49% | +17.24% | +174.91% | +344.55% | 15.65B | |
| -0.83% | +2.06% | +23.70% | +182.37% | 13.68B | |
| +6.42% | +12.51% | +41.09% | - | 12.97B | |
| Average | +1.72% | +5.50% | +40.02% | +118.03% | 23.68B | |
| Weighted average by Cap. | +0.43% | +6.55% | +54.74% | +129.72% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 81.46M 71.52M 65.83M 61.35M 116M 7.74B 118M 792M 307M 3.8B 306M 299M 13.23B | 124M 109M 100M 93.41M 176M 11.79B 180M 1.21B 467M 5.79B 466M 456M 20.15B |
| Net income | -136M -119M -110M -102M -193M -12.89B -196M -1.32B -511M -6.33B -509M -498M -22.02B | -117M -103M -94.62M -88.17M -166M -11.13B -170M -1.14B -441M -5.46B -440M -430M -19.02B |
| Net Debt | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-07-01 | US$1.140 | +6.54% | 1,749,509 |
| 26-06-30 | US$1.070 | +3.88% | 890,283 |
| 26-06-29 | US$1.030 | +0.98% | 1,039,823 |
| 26-06-26 | US$1.020 | -1.92% | 4,447,685 |
| 26-06-25 | US$1.040 | -2.80% | 1,730,608 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ADCT Stock
Select your edition
All financial news and data tailored to specific country editions
